Camurus AB (CAMX)

Currency in SEK
669.00
-16.00(-2.34%)
Closed·
CAMX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
CAMX is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
652.50675.00
52 wk Range
483.80740.00
Key Statistics
Prev. Close
685
Open
675
Day's Range
652.5-675
52 wk Range
483.8-740
Volume
115.48K
Average Volume (3m)
202.42K
1-Year Change
3.48%
Book Value / Share
65.14
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CAMX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
815.43
Upside
+21.89%
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins

Camurus AB News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Camurus AB Company Profile

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and phase III clinical trials to treat gastroenteropancreatic neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud’s phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM2056 that is in phase I clinical trials for the treatment of metabolic diseases; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; and Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity, as well as NewBridge Pharmaceuticals. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.

Employees
267
Market
Sweden

Camurus AB Earnings Call Summary for Q2/2025

  • Q2 2025 EPS of 4.08 beat forecast by 24.77%; revenue of 675.5M SEK exceeded expectations by 7.34%
  • 52% YoY revenue growth; 25% market share in long-acting injectable buprenorphine market; 93.9% gross margin
  • EU approval for OXESSA received; strategic partnership with Eli Lilly announced for future growth
  • Full-year 2025 guidance maintained; targeting significant growth in Buvidal and Brixadi products
  • Stock declined 1.09% despite earnings beat; trading near 52-week high with high earnings multiples
Last Updated: 17/07/2025, 14:28
Read Full Transcript

Compare CAMX to Peers and Sector

Metrics to compare
CAMX
Peers
Sector
Relationship
P/E Ratio
55.3x0.0x−0.5x
PEG Ratio
0.260.000.00
Price/Book
10.3x0.0x2.6x
Price / LTM Sales
17.5x0.0x3.3x
Upside (Analyst Target)
16.6%0.0%45.4%
Fair Value Upside
Unlock0.0%7.7%Unlock

Analyst Ratings

5 Buy
1 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 815.43
(+21.89% Upside)

Earnings

Latest Release
Jul 17, 2025
EPS / Forecast
4.08 / 3.42
Revenue / Forecast
675.50M / 637.42M
EPS Revisions
Last 90 days

CAMX Income Statement

People Also Watch

308.8
NOVOb
-1.81%
323.40
BONEX
-2.18%
260.07
AVAV
-2.83%
863.00
EVOG
-1.08%
44.4
NIBEb
-1.55%

FAQ

What Stock Exchange Does Camurus AB Trade On?

Camurus AB is listed and trades on the Stockholm Stock Exchange stock exchange.

What Is the Stock Symbol for Camurus AB?

The stock symbol for Camurus AB is "CAMX."

What Is the Camurus AB Market Cap?

As of today, Camurus AB market cap is 39.75B.

What Is Camurus AB's Earnings Per Share (TTM)?

The Camurus AB EPS (TTM) is 12.23.

When Is the Next Camurus AB Earnings Date?

Camurus AB will release its next earnings report on 05 Nov 2025.

From a Technical Analysis Perspective, Is CAMX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Camurus AB Stock Split?

Camurus AB has split 1 times.

How Many Employees Does Camurus AB Have?

Camurus AB has 267 employees.

What is the current trading status of Camurus AB (CAMX)?

As of 03 Aug 2025, Camurus AB (CAMX) is trading at a price of 669.00, with a previous close of 685.00. The stock has fluctuated within a day range of 652.50 to 675.00, while its 52-week range spans from 483.80 to 740.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.